Liver fat study for people with obesity
Treatments studied
Part of Hormones & metabolism clinical trials.
This study looks at liver fat and how to manage it in people with obesity. It may help find better ways to treat fatty liver disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Body mass index (BMI) between 30 and 50
- Liver has moderate to severe fat buildup (stage 2 or 3)
- No type 1 diabetes
- Alcohol intake within recommended limits
- No other liver diseases, recent weight-loss drugs, or surgery
- Not pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding a new medicine, CS0159, to a standard diabetes drug (semaglutide) can improve liver health and blood sugar in people with fatty liver disease, obesity, and type 2 diabetes. It may help reduce liver fat and support weight loss.
This study tests a high dose of semaglutide (a medicine used for weight management) to see how it affects stomach emptying in people with excess weight. Participating may help understand how this treatment works and could lead to better options for weight loss.
This study tests a new medicine called survodutide to see if it can improve heart function and structure in people who are overweight and have fatty liver disease. It may help reduce risks related to heart problems.
This Phase 2 study tests how semaglutide (a diabetes medication also used for weight) affects fatty liver and the liver’s response to sugar. It may help people with non-alcoholic fatty liver disease understand whether the drug improves liver fat and related changes.
This study tests whether a weekly injection (a GLP-1 medication similar to semaglutide) can help people with obesity and fatty liver reduce their alcohol intake and improve liver health. It may be an option if you drink more than moderate amounts and have fatty liver.
This study tests a new drug called ALN-CIDEB for people with fatty liver disease (MASLD or MASH). The goal is to see if it can reduce liver fat and improve liver health. You may qualify if you have a higher BMI and evidence of liver fat on imaging tests.
Hear when a new Metabolic Associated Fatty Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.